Published：Jun 19, 00:33Last updated：Jun 20, 03:03

US Launches Trade Probe Into German Drug Pricing

Jun. 19, 2026 00:33

The US has initiated a Section 301 investigation into Germany, alleging persistent underpayment for innovative pharmaceutical products. This could lead to retaliatory tariffs on German goods. The probe was announced on June 19, 2026, and reflects ongoing trade tensions between the two nations.

Summarized

8News

6Media

Jun. 19, 2026 15:18

German Chancellor Friedrich Merz called for international discussions on exchange rates to address the EU’s growing trade deficit with China. The announcement was made on June 19, 2026, highlighting the EU’s determination to tackle trade imbalances through coordinated efforts on currency valuation.

Jun. 20, 2026 03:03

The United States launched an investigation on Friday, June 19, to determine whether Germany is paying fair prices for American drugs sold in its territory. This move could lead to retaliatory measures against Germany, including new taxes on German exports. The investigation marks another escalation in trade tensions between the two countries.

The United States has initiated a Section 301 trade investigation into Germany's pharmaceutical pricing policies, alleging systematic underpayment for innovative American medicines. Announced on June 19, 2026, the probe could result in retaliatory tariffs on German goods if violations are confirmed, marking a significant escalation in transatlantic trade tensions. U.S. Trade Representative Jamison Greer has proposed potential remedies including adjusted discount structures while requesting formal consultations with German authorities.Bloomberg+2

🔍 Investigation Focus

The probe specifically examines whether Germany's mandatory discount requirements for drugmakers create unfair trade disadvantages for U.S. pharmaceutical companies. Authorities will assess the extent of payment discrepancies and their commercial impact, with Berlin recently announcing plans to demand larger discounts from manufacturers. The investigation falls under Section 301 of U.S. trade law, previously used during the Trump administration.France 24+2

💊 Pharmaceutical Trade Dispute

At the heart of the conflict are Germany's regulated drug pricing mechanisms, which the U.S. claims disproportionately burden American innovators. The investigation follows Germany's move to expand discount requirements, potentially affecting profitability for U.S.-developed medications in one of Europe's largest pharmaceutical markets. No timeline has been disclosed for the probe's completion.Bloomberg+2

🌐 Diplomatic Reactions

German Chancellor Friedrich Merz responded by urging the U.S. to honor existing trade commitments with Europe, while separately calling for international dialogue on currency valuation to address EU-China trade imbalances. The dual statements reflect Germany's broader trade policy concerns beyond the pharmaceutical investigation.Bloomberg+2

⚖️ Potential Outcomes

If the investigation finds Germany in violation, possible U.S. actions include:

New tariffs on targeted German exports
Revised trade agreement terms
Sector-specific trade restrictions
The move comes amid ongoing negotiations about fair pricing for innovative medical treatments globally.Bloomberg+2

GermanyFriedrich Merzpharmaceutical pricingUS Trade RepresentativeSection 301 investigation